Skip to main content

Month: August 2025

NewtekOne, Inc. Closes Offering of Depositary Shares Each Representing 1/40th of an Interest in its Series 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B

BOCA RATON, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) — On August 20, 2025, NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) successfully closed an offering of 2,000,000 depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of the Company’s 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), with a liquidation preference of $1,000 per share (equivalent to $25.00 per Depositary Share). The offering generated approximately $48.357 million in net proceeds to the Company. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 150,000 Depositary Shares at the public offering price less the applicable underwriting discount. The newly issued Series B Preferred Stock will pay (and the holders...

Continue reading

Safety Shot Secures $30 Million Strategic Investment From BONK Core Team and FalconX

SCOTTSDALE, AZ, Aug. 25, 2025 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced it has successfully priced a $30 million financing, anchored by a consortium of strategic investors including FalconX, the transaction consists of a registered direct offering for approximately $5 million in cash and a concurrent private placement for $25 million paid for in BONK tokens by the BONK founding members, with all shares priced at $0.46 per share. Demonstrating significant investor demand for the Company’s new strategic direction, this powerful backing from some of the most respected names in both traditional and digital asset finance provides Safety Shot with a fortified balance sheet to aggressively execute on its growth strategy. For shareholders, we believe this transaction represents...

Continue reading

Forager Capital Management Submits Fully Financed Proposal to Acquire Quipt Home Medical for $3.10 Per Share in Cash

Acquisition Proposal is Fully Financed and Requires No Further Diligence—Ready for Definitive Documents Prepared to Improve Offer Upon Constructive Engagement from Board BIRMINGHAM, Ala., Aug. 25, 2025 (GLOBE NEWSWIRE) — Forager Capital Management (“Forager”), one of the largest shareholders of Quipt Home Medical Corp. (“Quipt”) (NASDAQ: QIPT; TSX: QIPT), with beneficial ownership of 9.7%, today announced it has submitted a proposal to acquire all outstanding shares of Quipt for $3.10 per share in cash (the “Acquisition Proposal”). The Acquisition Proposal is not subject to any due diligence or financing conditions and is capable of being executed immediately. The offer represents a 120% premium to Quipt’s unaffected share price of $1.41 at close on May 19, 2025, the trading day prior to Forager’s prior proposal being made public. In...

Continue reading

VERSES® Receives Patent for Specifying Domain Models with Active Inference Agents

Patent Illustrates Additional Component of Company’s Commercial Strategy VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, today announces that a patent was issued by the US Patent and Trademark office to the VERSES team. The patent, entitled, “A Method and System for Specifying an Active Inference based agent using Natural Language”, presents a novel approach for designing domain models that is designed to enable software agents to generate predictions and carry out domain-specific tasks. “This patent represents just a glimpse of how VERSES is turning active inference into usable, scalable technology,” said Hari Thiruvengada, Chief Technology Officer of VERSES....

Continue reading

AITX’s RAD Launches Logistics Market Solution With ROAMEO

Client Feedback from Complete RAD Security Solution Offers Significant Potential Detroit, Michigan, Aug. 25, 2025 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced an expanded emphasis on serving the logistics sector. This initiative is driven by strong client response to the recent addition of ROAMEO™ Gen 4 and SARA™ to RAD’s security solutions. With deep industry ties, a proven track record, and the breadth of its complete ecosystem, the Company sees significant opportunities for expansion. As part of the support for this effort the company has issued a fully refreshed Logistics Solution brochure, that can be found here: www.radsecurity.com/brochures/RAD-Logistics-2508.pdf “Encouragement...

Continue reading

Mama’s Creations to Host Second Quarter Fiscal 2026 Earnings Call on September 8 at 4:30 p.m. Eastern Time

EAST RUTHERFORD, NJ, Aug. 25, 2025 (GLOBE NEWSWIRE) — Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh Deli prepared foods, will release financial results for the fiscal second quarter ended July 31, 2025 after market close on September 8, 2025. Management will host an investor conference call at 4:30 p.m. Eastern time on Monday, September 8, 2025 to discuss the Company’s second quarter fiscal 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information: Q2 FY2026 Earnings Conference Call Date: Monday, September 8, 2025 Time: 4:30 p.m. Eastern time U.S. Dial-in: 1-877-451-6152International Dial-in: 1-201-389-0879Conference ID: 13755525Webcast: MAMA Q2 FY2026 Earnings Conference Call Please...

Continue reading

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the final patient in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris (AV) completed participation on August 22, 2025. Acne vulgaris is a common skin condition characterized by inflammatory and non-inflammatory...

Continue reading

Schouw & Co. share buy-back programme, week 34 2025

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025.   The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).  Trading day No. of shares Average price Amount    Accumulated until 15 August 2025 99,500 597.56 59,457,510    Monday, 18 August 2025 2,000 582.18 1,164,360    Tuesday, 19 August 2025 1,500 603.63 905,445    Wednesday, 20 August 2025 1,500 600.17 900,255    Thursday, 21 August 2025 1,500 597.75 896,625    Friday,...

Continue reading

Danforth Advisors Acquires PharmaDirections, Expanding its Integrated Drug Development Services from Discovery through Commercialization

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Danforth Advisors, LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and execution from company incubation to approval. The team’s expertise spans discovery, early to late stage non-clinical and clinical development, translational sciences, and all areas of CMC with full program and alliance management oversight across all major modalities and therapeutic areas. Michelle Higgin, PhD, will continue in her role as CEO. “PharmaDirections and...

Continue reading

GCL’s Subsidiary Completes Compulsory Acquisition and Delisting of Ban Leong Technologies Limited

SINGAPORE, Aug. 25, 2025 (GLOBE NEWSWIRE) — GCL Global Holdings Ltd (NASDAQ: GCL) (“GCL”), a leading provider of games and entertainment and the indirect parent company of Epicsoft Asia Pte. Ltd. (“Epicsoft Asia” or “Offeror”), today announced that Epicsoft Asia has completed the compulsory acquisition of Ban Leong Technologies Limited (“Ban Leong”) on August 25, 2025, and Ban Leong will be delisted from the Singapore Stock Exchange on August 26, 2025. For over three decades, Ban Leong has been a leading distributor of technology products across Asia, offering an extensive portfolio that includes IT accessories, gaming components, smart (IoT) devices, and commercial solutions. The company is an authorized distributor for more than 50 globally recognized brands, including Razer, Nvidia, Samsung, Huawei, TP-Link, and LG. Leveraging...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.